Ophthalmic gene therapy company Beacon Therapeutics was launched in June 2023 with a £96m ($120m) series A financing. The company was created by VC firm Syncona Investment Management, which combined Applied Genetic Technologies Corporation’s late-stage program in X-linked retinitis pigmentosa (XLRP) with two preclinical programs.
Beacon represents the second attempt from the team that created Nightstar Therapeutics plc to see a gene therapy treatment...